CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
CO33: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
The Web Application Developer is responsible for the entire project/software lifecycle which consists of the following components: application architecture, input/output design, system specifications, process mapping, user requirements, layouts, user interface, database design/programming, test plans and training.
Find out how to apply.
Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable).
Dr. Ralph Meyer Phase III Young Investigator Award
Congratulations from everyone at CCTG, The Ralph Meyer Young Investigator Award was presented to Dr Prica at the Annual Spring Meeting last week. The award hours MD, fellow, PhD within 10 years of certification / first faculty appointment or current fellow who has either spent time at CCTG Central Office, worked on Phase III projects with Disease Site Committees / Endpoint Committees / Working Groups, or who has contributed significantly to the conduct of a Phase III trial at a centre.
